BRIEF published on 11/12/2025 at 08:05, 2 months 23 days ago Pentixapharm publie ses résultats financiers pour les 9 premiers mois de 2025 Perte Financière Revenu Pentixapharm Résultats À 9 Mois Ajustement Des Directives
PRESS RELEASE published on 11/12/2025 at 08:00, 2 months 23 days ago Pentixapharm Publishes 9-Month Figures for 2025 Pentixapharm announces 9-month figures for 2025, reports €12.7 million loss. Adjusted guidance projects approximately €18 million loss for the fiscal year. New financial statements available on website Financial Statements 2025 Loss 9-month Figures Pentixapharm
BRIEF published on 11/10/2025 at 08:05, 2 months 25 days ago Pentixapharm publiera ses résultats financiers pour le troisième trimestre et les neuf premiers mois de 2025. Résultats Financiers Biotechnologie Oncologie Produits Radiopharmaceutiques Pentixapharm
BRIEF published on 11/10/2025 at 08:05, 2 months 25 days ago Pentixapharm to Release Financial Results for Q3 and Nine Months of 2025 Financial Results Oncology Biotech Radiopharmaceuticals Pentixapharm
PRESS RELEASE published on 11/10/2025 at 08:00, 2 months 25 days ago Pentixapharm to Report Third Quarter and First Nine Months 2025 Financial Results on Wednesday, November 12, 2025 Pentixapharm Holding AG to release Third Quarter and First Nine Months 2025 Financial Results on November 12, 2025. Conference call and webcast to follow Financial Results Conference Call Berlin Radiopharmaceuticals Pentixapharm
BRIEF published on 11/06/2025 at 20:00, 2 months 28 days ago Pentixapharm Holding AG réduit ses prévisions de pertes pour 2025 Développement Clinique Prévisions Financières Réduction Des Coûts Industrie Biotechnologique Optimisation Stratégique
BRIEF published on 11/06/2025 at 20:00, 2 months 28 days ago Pentixapharm Holding AG Reduces Projected Loss for 2025 Biotech Industry Clinical Development Cost Reduction Financial Forecast Strategic Optimization
PRESS RELEASE published on 11/06/2025 at 19:55, 2 months 28 days ago EQS-Adhoc: Pentixapharm Holding AG: Pentixapharm significantly reduces projected loss for financial year 2025 Pentixapharm Holding AG significantly reduces projected loss for financial year 2025 due to clinical development program realignment Clinical Development Realignment Pentixapharm Financial Year 2025 Projected Loss
BRIEF published on 10/23/2025 at 22:17, 3 months 12 days ago Pentixapharm recentre sa stratégie et réduit ses coûts Développement Clinique Réduction Des Coûts Produits Radiopharmaceutiques Réduction Des Effectifs Stratégie Biotechnologique
BRIEF published on 10/23/2025 at 22:17, 3 months 12 days ago Pentixapharm Refocuses Strategy and Reduces Costs Clinical Development Cost Reduction Radiopharmaceuticals Workforce Reduction Biotech Strategy
Published on 02/05/2026 at 13:30, 35 minutes ago Nextech3D.ai to Report Q3 2025 Earnings After Market Close on February 18, 2026
Published on 02/05/2026 at 13:30, 35 minutes ago ESGold Expands Montauban Land Position Following 3D Geological Model Identifying Potential District-Scale Mineralized Corridor
Published on 02/05/2026 at 13:20, 45 minutes ago Guanajuato Silver Sees Significant Growth in Resources at Valenciana
Published on 02/05/2026 at 13:15, 50 minutes ago Avino Appoints Linda Broughton to The Board of Directors
Published on 02/05/2026 at 13:00, 1 hour 5 minutes ago urban-gro to Implement 1-for-25 Reverse Stock Split
Published on 02/05/2026 at 13:30, 35 minutes ago Ascory Bank ends its year of transformation in 2025 with positive results and starts 2026 with a new strategy and a new name
Published on 02/05/2026 at 13:04, 1 hour 1 minute ago EQS-Adhoc: Ascory Bank AG raises earnings forecast for financial year 2025
Published on 02/05/2026 at 12:48, 1 hour 16 minutes ago Turkiye Garanti Bankasi A.S.: Announcement regarding forward looking statements on the expectations for the year 2026
Published on 02/05/2026 at 12:45, 1 hour 20 minutes ago R.E.A. Holdings plc: Notification of Major Holdings
Published on 02/05/2026 at 11:47, 2 hours 18 minutes ago Worthington Steel Announces Start of Acceptance Period for All-Cash Tender Offer of €11.00 per Share to Shareholders of Kloeckner & Co SE
Published on 02/05/2026 at 11:30, 2 hours 35 minutes ago Déclaration nombre d'actions et droits de vote - 05.02.2026
Published on 02/05/2026 at 11:30, 2 hours 35 minutes ago Disclosure of shares outstanding and voting rights - 05.02.2026
Published on 02/04/2026 at 18:04, 20 hours 1 minute ago Total number of voting rights and shares making up the share capital at January 31, 2026
Published on 02/04/2026 at 17:45, 20 hours 20 minutes ago Information concerning the total number of voting rights and shares 2026 01 31
